Principal Investigator
Hadar Lev-Tov
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20260503
Clinical Trial Summary
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other